I don't know but isn't anyone worried by the fact that Bliss-76 bombed at 76 weeks and at 52 weeks the 10mg dose was barely working? It looks like the drug performed badly in North American and Europe and only performed well in Asia, South America and Eastern Europe. This raises questions about efficacy and population related genetic differences. The data in North America and Europe wasn't very good. .021 is statistically significant at 10 mg's but not quite so robust as was seen in the first trial. And at 76 weeks the efficacy was gone. I'm concerned with the data. This valuation is too high.